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Abstract
Background: Solid pseudopapillary neoplasms of the pancreas (SPN) are rare tumors affecting mainly women. They
show an activating mutation in CTNNB1, the gene for β-catenin, and consequently an overactivation of the Wnt/
β-catenin pathway. This signaling pathway is implied in the pathogenesis of various aggressive tumors, including
pancreatic adenocarcinomas (PDAC). Despite this, SPN are characterized by an unusually benign clinical course.
Attempts to explain this lack of malignancy have led to the discovery of an aberrant expression of the transcription
factor FLI1 in SPN.
Methods: In 42 primary pancreatic tumors the RNA-expression of the FLI1 targets DKK1, INPP5D, IGFBP3 and
additionally two members of the Wnt/β-catenin pathway, namely BCL9 and BCL9L, was investigated using
quantitative real time PCR. Expression of these genes was evaluated in SPN (n = 18), PDAC (n = 12) and the less
aggressive intraductal papillary mucinous neoplasm IPMN (n = 12) and compared to normal pancreatic tissue.
Potential differences between the tumor entities were evaluated using students t-test.
Results: The results demonstrated a differential RNA-expression of BCL9L with a lack of expression in SPN (p < 0.001),
RNA levels similar to normal tissue in IPMN and increased expression in PDAC (p < 0.04). Further, overexpression of the
cyclin D1 inhibitor INPP5D in IPMN (p < 0.0001) was found. PDAC, on the other hand, showed the highest expression
of IGFBP3 (p < 0.00001) with the gene still being significantly overexpressed in IPMN (p < 0.001). Nevertheless the
difference in expression was significant between PDAC and IPMN (p < 0.05) and IGFBP3 RNA levels were significantly
higher in PDAC and IPMN than in SPN (p < 0.0001 and p < 0.02, resp.).
Conclusions: This study demonstrates a significantly decreased expression of the β-catenin stabilizing gene BCL9L in
SPN as a first clue to the possible reasons for the astonishingly benign behavior of this entity. In contrast, high
expression of the gene was detected in PDAC supporting the connection between BCL9L expression and tumor
malignancy in pancreas neoplasias. IPMN, accordingly, showed intermediate expression of BCL9L, but instead
demonstrated a high expression of the cyclin D1 inhibitor INPP5D, possibly contributing to the better prognosis of this
neoplasia compared to PDAC.
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Background
Solid pseudopapillary neoplasms of the pancreas (SPN)
are rare tumors affecting women in the overwhelming
majority of cases. 90–95 % of these neoplasms are clinic-
ally benign and only few cases show malignant growth
with metastases in liver and mesenterium. At the mo-
lecular level SPN are defined by a mutation in exon 3 of
CTNNB1, the gene for β-catenin, found in about 90 %
of cases [1]. β-catenin is part of the Wnt signaling
pathway and plays a crucial role in embryonal develop-
ment, but its deregulated activity has been implicated in
the pathogenesis of a variety of cancers [2] and specific-
ally in pancreatic cancer [3]. The activating mutation of
CTNNB1 in SPN is often associated with an overexpres-
sion of cyclin D1 (70 % of cases) [4]. Deregulated
expression of cyclin D1 is found in a large variety of ma-
lignancies and often associated with tumor progression
[5]. Despite activating mutations in β-catenin and over-
expression of cyclin D1 SPN are largely benign tumors
and the reason for this benign behavior remains elusive.
A specific feature correlated with overexpression of
cyclin D1 in SPN is the aberrant expression of the tran-
scription factor FLI1 [6]. This transcription factor is well
known as one part of the EWS/FLI1 fusion protein,
product of the translocation t(11;22)(q24;q12) and defin-
ing feature of Ewing sarcomas. A large part of the
functional knowledge about FLI1 has been derived from
studying this fusion product. The EWS/FLI1 fusion
protein largely retains the DNA binding specificity of
FLI1 [7, 8] and studying its regulatory function several
genes of interest have emerged that may also play a role
in SPN.
FLI1 interacts with the Wnt/β-catenin pathway by
regulating the expression of the Wnt inhibitor DKK1. In
the form of EWS/FLI1 the transcription factor inhibits
the expression of DKK1 in Ewing sarcomas [9] but its
role in SPN is still unknown. Other members of the
Wnt/β-catenin pathway are the BCL9 and BCL9L
proteins that may stabilize β-catenin and support its
transcription inducing function. The tumor promoting
function of both genes has mainly been studied in colon
cancer so far [10, 11], but given the known role of the
Wnt signaling pathway in pancreatic neoplasias and es-
pecially SPN their function in these tumors needs to be
investigated. A target gene of FLI1 itself without the
fusion partner is INPP5D (SHIP1) [12]. This protein in-
hibits D-type cyclins, including cyclin D1, in osteoclast
precursors in an Akt dependent manner [13]. In con-
cordance with this is an increased expression of p27,
also regulated via the Akt pathway. Elevated levels of
p27 and p21 have already been demonstrated in SPN
[14]. In pancreatic adenocarcinomas the Akt pathway is
activated by IGF and the ratio of IGF and its inhibitor
IGFBP3, another target of EWS/FLI1 [15], may play a
role in the development of pancreatic cancer [16].
Additionally, overexpression of IGFBP3 was found in
pancreatic cancer cells [17] and has been shown to pro-
mote metastases in pancreatic endocrine neoplasms
[18]. The IGF-1 pathway is also critical for the pathogen-
esis and proliferation of Ewing sarcomas and directly
regulated by EWS/FLI1 [19, 20]. In Ewing sarcoma cell
lines EWS/FLI1 suppresses expression of IGFBP3 [15],
but the transcriptional activity of the wildtype transcrip-
tion factor FLI1 in SPN may differ. Also involved in the
Akt pathway and dependent on IGF signaling is the
EWS/FLI1 target PBK (also called TOPK) [21, 22]. PBK
phosphorylates and activates Akt and contributes to the
degradation of its inhibitor PTEN [23].
The objective of this study was to elucidate the
molecular basis for the astonishingly benign behavior
of SPN in the face of an activated Wnt pathway and
additionally an overexpression of cyclin D1, two fac-
tors usually associated with aggressive malignancies.
To this purpose the RNA expression of the FLI1 reg-
ulated genes DKK1, INPP5D, IGFBP3 and PBK and of
FLI1 itself was investigated. Additionally, to further
evaluate the Wnt/β-catenin pathway the expression of
its members BCL9 and BCL9L was examined. By
correlating the RNA expression of the various genes
with the expression of FLI1 we further addressed the
question of the role of FLI1 overexpression in SPN.
Identifying factors that render SPN benign may in re-
verse shed light on factors underlying the aggressive




Eighteen tumor resection specimens of solid pseudopa-
pillary neoplasms (SPN) of the pancreas were obtained
from the consultation files of Prof. Günter Klöppel,
former head of the Department of Pathology of the Uni-
versity of Kiel. Additionally 12 tumor resection speci-
mens of pancreatic adenocarcinoma (PDAC) and
intraductal papillary mucinous neoplasm (IPMN) each
were obtained from the archive of the MVZ Hanse
Histologikum in Hamburg. The study was non-
interventional and samples investigated in this study
were acquired during necessary medical procedures and
submitted for clinically indicated diagnostic procedures
to this Institute. All samples were anonymized at the
start of the study. This country’s (Germany) ethics pol-
icies and medical research laws do not require approval
by an ethics committee when leftover diagnostic material
is used in research in accordance with the Declaration of
Helsinki. Written informed consent to use leftover diag-
nostic material for research purposes was obtained from
all patients included in the study that were still alive.
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RNA-Extraction and quantitative real time PCR
Tumor tissue of pancreatic neoplasias was manually mi-
crodissected from formalin fixed, paraffin embedded tissue
blocks. For IPMN samples, Laser-microdissection was per-
formed because of the rarity of the tumor cells. After
microdissection each sample contained at least 75 % of
tumor cells. Total RNA was extracted using the RNeasy
FFPE kit (Qiagen, Germany). To evaluate the RNA expres-
sion of the genes FLI1 (NCBI RefSeq: NM_002017.4),
DKK1 (RefSeq: NM_012242.2), INPP5D (SHIP1) (RefSeq:
NM_005541.4), PBK (TOPK) (RefSeq: NM_018492.3),
IGFBP3 (RefSeq: NM_000598.4), and BCL9 (RefSeq:
NM_004326.3) and BCL9L (RefSeq: NM_182557.2) quan-
titative real time RT-PCR was performed on the StepOne
Real Time PCR System (Life Technologies, USA) using the
Qiagen OneStep RT-PCR kit (Qiagen, Germany) according
to the manufacturer’s instructions. For each PCR 50 cycles
were run consisting of 15 sec. at 96 °C and 1 min at 60 °C
following an initial reverse transcription step of 30 min at
50 °C and 15 min at 96 °C. TaqMan MGB-probes were
used for detection of the PCR product. Primers and probes
for each analyzed gene are given in Table 1. Relative ex-




mean control – mean sampleð Þ
2ΔCPref mean control – mean sampleð Þ
using normal pancreatic tissue (NPT) as control tissue
and GAPDH as reference gene for normalization. The
mean ratio from two independent experiments was used.
The NPT control sample was prepared from RNA
pooled from nine different patients.
Statistical analysis
Expression levels of RNA in SPN, PDAC and IPMN
were compared to normal pancreatic tissue and between
the different tumor entities using Student’s t-test. Ratios
were normalized and linearized using binary logarithm.
Correlations of the expressions of different genes were
analyzed using Pearson’s correlation coefficient.
Results
Eighteen cases of solid pseudopapillary neoplasms of the
pancreas were evaluated for RNA expression levels of
FLI1, DKK1, INPP5D (SHIP1), IGFBP3, PBK (TOPK),
and BCL9 and BCL9L. Microdissection of the tissue en-
sured a high proportion of tumor cells (75 % or above)
in the investigated sample. The original RNA expression
data are provided in Additional file 1. Expression of FLI1
was increased up to 48 fold in all but 3 of the 18 SPN
samples (83 %). In 9 samples FLI1 expression was more
than 10 fold higher than in normal pancreatic tissue
(NPT), making this overall a very clear and highly signifi-
cant increase (p < 0.0001, Fig. 1a). In IPMN FLI1 expres-
sion was increased 2–5 fold in 8 out of 12 samples, the
increase being significant (p < 0.001, Fig. 1a). In PDAC,
however, FLI1 expression was only increased in 5 of the
12 samples (42 %). There was no significant difference to
FLI1 expression in normal tissue (p < 0.08, Fig 1a). FLI1
expression was also significantly higher in SPN than in
IPMN or PDAC (p < 0.05 and p < 0.015 resp.).
No significant difference in the expression levels of
INPP5D was found between SPN or PDAC samples and
NPT (Fig. 1b). However, a clear and highly significant in-
crease in expression of INPP5D was found in 10 out of
12 samples of IPMN, the increase ranging between 4
and 10 fold (p < 0.0001, Fig. 1b). INPP5D expression was
also significantly higher in IPMN than in SPN (p < 0.03,
Fig. 1b), but no significant difference was detected be-
tween IPMN and PDAC (p < 0.08).
Expression of IGFBP3 was highly increased up to 160 fold
in all but one of the PDAC samples, as expected (p <
0.00001, Fig. 1c). A similar result was seen for IPMN, where
again the expression was increased in all but one case up to
55 fold (p < 0.001, Fig. 1c). On the other hand, in SPN no
significant increase in the expression of IGFBP3 was found.
The differences between the three entities were significant,
too, with PDAC showing a higher expression of IGFBP3 than
IPMN (p < 0.05) and SPN (p < 0.0001) and IPMN still dem-
onstrating a higher expression than SPN (p < 0.02, Fig. 1c).
BCL9 and BCL9L are very similar genes that are sup-
posed to have a similar function in the Wnt pathway.
Table 1 Primers and probes
Gene Primers (for/rev) Probe
GAPDH TTTGGTATCGTGGAAGGACTC / GAACATCATCCCTGCCTCTAC CATGCCATCACTGCC
FLI1 CCAGATCCGTATCAGATCCTG / CAACGCCAGCTGTATCACCT CAGATCCAGCTGTGGCAA
DKK1 GCATGCGTCACGCTATGTGC / TGGTAATGATCATAGCACCTTGG CTGATCAAAATCATTTCC
INPP5D ACGGAGCGTGATGAATCCAG / CAGCATCACTGAAATCATCAAC AAGTCACTAGCAGGGCC
IGFBP3 ACTACGAGTCTCAGAGCACAG / GACACACTGAATCACCTGAAG ACGGCAGGGACCATA
PBK TGTTATTACTGACAAGGCAGAC / GATGAAGCATACTATGCAGCG ATGACTTTATCGATTCCAC
BCL9 CCATGATGCTATCAAGACTGTG / CGAGGATTCTGTGTATTAATGC CCAGCTCAGATGACGAC
BCL9L CACAATGCCATCAAGACCATC / AGTTCAGGTGCATCTGGCTG TCAGACGACGAGCTGC
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Nevertheless, they showed differing expression patterns
in pancreatic neoplasias. No significantly different ex-
pression of BCL9 was found between normal tissue and
any of the pancreatic neoplasias investigated (Fig. 1d).
BCL9L expression, however, was significantly increased
in PDAC (p < 0.04, 6 of 11 samples), but significantly de-
creased in SPN (p < 0.001, 10 of 17 samples, Fig. 1e). In
IPMN the expression of BCL9L overall showed no sig-
nificant difference to normal tissue, although some cases
demonstrated a strongly reduced expression (Fig. 1e).
No correlation was found between the BCL9L ratio and
the grade of dysplasia or the histological type of the
IPMN (not shown).
Expression levels of PBK were very low in all pancreas
tissues (normal and neoplastic), making a meaningful
analysis of changes in RNA expression not feasible.
Furthermore, DKK1 expression was extremely low in
normal pancreatic tissue, but somewhat higher in 11 of
18 (61 %) samples of SPN, 6 of 12 (50 %) samples of
IPMN and 10 of 12 (83 %) samples of PDAC. However,
the overall very low expression of the DKK1-RNA made
a statistical analysis of the ratios unreliable. Neverthe-
less, the DKK1 expression in any pancreatic neoplasia
seems to be higher than in normal tissue.
Expression levels of the transcription factor FLI1 in SPN
demonstrated a significant positive correlation of a linear
type to the expression of INPP5D (r = 0.88; p < 0.00001,
Fig. 2) and IGFBP3 (r = 0.84; p < 0.00001, not shown),
although both these genes did not show significantly
increased RNA expression in SPN. In PDAC, however,
only FLI1 and INPP5D showed a strong positive correl-
ation (r = 0.97; p < 0.00001, Fig. 2), although neither gene
Fig. 1 Expression of FLI1, INPP5D, IGFBP, BCL9, and BCL9L in pancreatic tumors. RNA expression of FLI1 (a), INPP5D (b), IGFBP (c), BCL9 (d), and
BCL9L (e) in various pancreatic neoplasias. The expression was normalized against GAPDH and a pool of normal pancreatic tissues (NPT) was used
as control sample, rendering the expression in NPT = 1, as demonstrated by the red line. For each entity the median expression is indicated by a
black line and error bars indicate the interquartile range. Statistical differences in RNA expression between different pathological entities are
shown above the groups and significance levels are indicated as p-values using Student’s T-test
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was highly expressed. No correlation, however, was found
between FLI1 and IGFBP3. No correlation between FLI1
and these two genes was detected in IPMN (Fig. 2).
Discussion
SPN are rare tumors of the pancreas with few cases
showing metastatic disease. Over 90 % of cases carry a
mutation in CTNNB1, the β-catenin gene, leading to ac-
tivation of the Wnt signaling pathway. Aberrant protein
expression and increased activity of the Wnt pathway
has been implicated in the pathogenesis of various
neoplasias, including pancreatic adenocarcinoma [2, 3].
In SPN, on the other hand, the β-catenin mutation does
not lead to an increased proliferation rate and malignant
behavior. The reason still remains to be elucidated. There-
fore, in this study, SPN were compared to the aggressively
behaving PDAC and furthermore to IPMN. The latter en-
tity behaves less aggressively than PDAC but is more ag-
gressive than SPN depending on the grade of dysplasia
and accompanying invasive adenocarcinoma.
A further factor associated with SPN is the transcrip-
tion factor FLI1. Aberrant protein expression has been
demonstrated in 63 % of cases [6]. The overexpression
of FLI1 in SPN has been confirmed in this study show-
ing a major increase in FLI1 RNA level in 83 % of cases
of SPN compared to only 50 % of PDAC and a much
less prominent increase in FLI1 expression levels in
IPMN. Functionally, FLI1 is linked to the Wnt pathway
by regulating the expression of the Wnt inhibitor DKK1
[9]. In Ewing’s sarcoma the fusion protein EWS/FLI1 in-
hibits basal and β-catenin induced transactivation of the
DKK1 promoter [9]. It has been hypothesized that this
decrease in DKK1 expression may contribute to the
aggressive and highly malignant behavior of Ewing’s
sarcomas. There are also hints of an overexpression of
DKK1 in especially aggressive pancreatic adenocarcin-
omas [24]. The present study, however, did not confirm
a high expression of DKK1 in pancreatic tumors. The
expression was generally very low in all tumor entities
and SPN, too, are no exception. Therefore an inhibition
of DKK1 is not verifiable here and most probably does
not play a part in the low malignancy of SPN.
The IGF-1 pathway is functionally important for the
pathogenesis and progression of Ewing Sarcoma [19, 21]
and the fusion protein EWS/FLI1 has been shown to
downregulate the expression of IGFBP3 in Ewing
sarcoma cell lines [15]. However, an effect of the tran-
scription factor FLI1 on IGFBP expression levels was not
confirmed in most pancreatic tissues. In SPN even a
highly significant overexpression of FLI1 is not enough
to change IGFBP3 levels from those in normal pancre-
atic tissue. In contrast, PDAC show a very high overex-
pression of IGFBP3, confirming the results of studies on
pancreatic cancer cell lines [17]. This is rather surpris-
ing, since high serum levels of IGFBP3 are supposed to
inhibit IGF1, thereby reducing the availability of a rele-
vant growth factor for PDAC and the relative levels of
IGFBP3 and IGF in serum have been associated with risk
of pancreatic cancer, at least in some studies [16, 25]. A
possible explanation may be provided by the fact that
IGFPB3 seems to be upregulated in pancreatic cancer
cells under hypoxic stress [26] and pancreatic xenograft
tumors under neoadjuvant therapy [27]. IGFBP3 may be
overexpressed due to stressful conditions to downregu-
late growth and allow the pancreatic cancer cell to sur-
vive in an adverse environment with limited resources.
In this theory, lack of overexpression of IGFBP3 in SPN
and, to a lesser extent, in IPMN may actually be a result
and not a cause for the benign behavior of SPN and the
less aggressive behavior of IPMN, since the generally
Fig. 2 Correlation of the expressions of FLI1 and INPP5D. The RNA expressions of FLI1 and INPP5D correlate well in PDAC (green), and to a lesser
extent in SPN (red). In IPMN (blue) a correlation between the two RNA expressions is not detectable. The line indicates the overall correlation
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slower growth of these tumors can be sustained more
easily when resources become limited.
INPP5D is a cyclin D1 inhibitor in osteoclast precursors
and also regulated by FLI1 [12]. Cyclin D1 is overex-
pressed in SPN but obviously functionally at least in part
inactive since the Rb protein is not phosphorylated in
SPN [14]. Overexpression of a cyclin D1 inhibitor would
account for this lack of downstream activity, but INPP5D
does not show a significant rise in RNA-expression levels
in SPN compared to normal pancreas tissue or PDAC,
although its expression seems to be closely correlated with
FLI1 expression in both SPN and PDAC. On the other
hand, the more common cyclin D1 inhibitors p21 and p27
have already been shown to be expressed in practically all
SPN [14]. Therefore, this functional niche may already be
occupied in this tumor entity. PDAC, on the other hand,
show aberrant and increased expression of cyclin D1 in
70-80 % of cases (reviewed in [28]) and cyclin D1 is
functionally active and relevant for cancer growth and
proliferation [29, 30]. Accordingly, the cyclin D1 inhibitor
INPP5D shows no increased expression in this entity.
However, INPP5D is overexpressed in IPMN, a less ag-
gressive form of pancreatic neoplasia. Data on cyclin D1
expression in IPMN are sparse, but its expression seems
to be higher in PDAC than in IPMN [31]. Overexpression
of the inhibitor INPP5D may factor in generating this dif-
ference and possibly even play a role for the less aggressive
growth of IPMN. SPN, on the other hand, seem to follow
a different route in pathogenesis where INPP5D is not in-
volved. This again demonstrates the general divergence of
SPN from ductal derived pancreatic neoplasias. IPMNs
are, however, also the only one of the three pancreatic
tumor entity investigated where no correlation was found
between FLI1 and INPP5D expression. In SPN and PDAC,
on the other hand the expression of FLI1 showed a posi-
tive correlation to the expression of INPP5D. This is an
indication that FLI1 may indeed play a role in the tran-
scription of INPP5D in pancreatic tissues. Nevertheless, in
leukemogenesis a negative regulation of INPP5D by FLI1
is described whereas in pancreatic tissue the correlation
was positive. Tissue specific modifications in the function
of the transcription factor may explain this difference.
BCL9 and BCL9L both are part of the Wnt/β-catenin
signaling pathway. Although the evidence for their exact
roles is somewhat sketchy and inconsistent, there seems
to be a consensus that both genes enhance Wnt-
signaling by binding to and increasing β-catenin tran-
scriptional activity. This further leads to increased
oncogenic signaling [10, 11, 32]. Nevertheless, most in-
vestigations were done on colon cancer or leukemia/
lymphoma cell lines and so far evaluations of pancreatic
cells concerning these two genes are not known. This
study demonstrates no difference in the expression of
BCL9 in the various types of pancreatic neoplasias we
evaluated compared to normal tissue. BCL9L, however,
showed a differential expression in SPN, IPMN, and
PDAC. Whereas the gene was clearly overexpressed in
the highly aggressive PDAC it also showed a decreased
expression in nearly 60 % of the mostly benign SPN.
IPMN, of intermediate malignant behavior, demon-
strated a high variance in the expression of BCL9L with
most cases showing an expression at the level of normal
pancreatic tissue. However, a few IPMN cases nearly
completely lacked expression of BCL9L. Overall the
expression of BCL9L nevertheless correlated with the
aggressiveness of the tumor. This is a strong hint that
BCL9L may contribute to overactivation of β-catenin
in PDAC [33, 34], especially since the overexpression
of the Wnt/β-catenin pathway seems to be correlated
with increased aggressiveness and exceptionally poor
prognosis [24, 35] via stabilization and activation of β-
catenin BCL9L may also promote the increased ex-
pression of the β-catenin target cyclin D1. On the
other hand, a lack of BCL9L expression in SPN may
lead to a faster degradation of β-catenin and reduced
function in the nucleus [10, 32], thereby preventing
the protein from fulfilling its transcriptional, and in this
case oncogenic, role.
Conclusions
This study provides a first clue to the possible reasons
for the astonishingly benign behavior of SPN by de-
monstrating a significantly decreased expression of the
β-catenin stabilizing gene BCL9L in this entity. The in-
volvement of the β-catenin gene in the pathogenesis of
SPN is already known, because of the high mutation fre-
quency of the gene (over 90 %) [1]. Therefore, an attenu-
ation of β-catenin function is needed to decrease the
oncogenic potential of the gene and account for the fa-
vorable prognosis of SPN. Moreover, the expression of
BCL9L was significantly increased in the aggressively
malignant PDAC, making a connection to the lack of
malignancy in SPN even more likely. Reasoning from
the point of view of PDAC, the high BCL9L expression
may in part contribute to its aggressive course. This
argument is further strengthened by the generally
intermediate position of the IPMN: intermediate in ma-
lignant behavior and intermediate in BCL9L expression.
On the other hand, IPMN may simply follow a function-
ally different pathogenetic path. Overexpression of the
cyclin D1 inhibitor INPP5D may be involved in the less
aggressive growth pattern of IPMN, but this mechanism
does not seem to play any role in the benign behavior
of SPN. When seen in context with other studies, the
high overexpression of IGFBP in PDAC and, to a lesser
extent also in IPMN may rather be a secondary event
and not contribute directly to the initiation of aggres-
sive malignancy.
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Additional file
Additional file 1: Mean RNA expression Ratio derived from two
independent experiments, normalized against GAPDH. (XLSX 12 kb)
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